Houston, TX - The novel inflammatory marker lipoprotein-associated phospholipase A 2 (Lp-PLA 2) and high-sensitivity C-reactive protein (hs-CRP) were higher in middle-aged men and women who ...

New Orleans, LA, November 9, 2004 – High levels of an enzyme – lipoprotein-associated phospholipase A2 (Lp-PLA2) – believed to trigger a cascade of inflammatory events in atherosclerosis can ...

(CHICAGO) - April 2, 2003 - Late-breaking data presented today at the American College of Cardiology's 52nd Annual Scientific Session show that both lipoprotein-associated phospholipase A2 (Lp-PLA2) ...

Researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans. UC Davis researchers have discovered that a blood component linked ...

WASHINGTON — Doctors are getting a new blood test to help predict which people with low cholesterol are at risk for heart disease. The Food and Drug Administration approved the PLAC test Friday. It ...

The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it ...

The Food and Drug Administration (FDA) has granted clearance for the PLAC Test for Lp-PLA2 Activity, a new test that predicts a patient’s risk of future coronary heart disease (CHD) events. The FDA’s ...

The FDA today announced clearance of a new screening test that predicts a patient’s risk for future CHD events. The agency has cleared the test for use in all adults with no history of CHD. However, ...

Coronary heart disease (CHD) kills more than 385,000 people in the United States each year, and more than half of those who die suddenly have no previous symptoms. A new blood test that could reduce ...

Ballantyne said the rationale for the analysis was to identify markers beyond traditional risk factors that would help predict the risk of stroke in apparently healthy adults, adding that LDL ...